ADS024 attenuates striatal dopamine loss and restores movement in animal models of Parkinson’s disease
Objective: To evaluate the effect of ADS024, an oral single strain live biotherapeutic product (SS-LBP), on the pathophysiology of MPTP-induced Parkinson’s Disease (PD) phenotypes in…A role of β2-adrenoreceptor agonist related to the development of Parkinson’s disease
Objective: To explore β2AR agonist’s effect on PD development with controlling for smoking. Background: Several studies have suggested the potential protective role of β2-adrenoreceptor agonist (β2AR…Neuroprotective effects of Ibudilast, a Phosphodiesterase IV inhibitor in mouse model of Parkinson’s disease
Objective: In the present study, we examined neuroprotective effects, if any, of IBD drug, a inhibitor of the phosphodiesterase IV in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse…Exenatide protects iPSC-derived dopaminergic neurons with A53T mutation through restoration of insulin signaling
Objective: Here we sought to investigate mechanisms by which insulin resistance affects PD pathogenesis in-vitro, and whether restoration of insulin signaling, using GLP-1 agonist exenatide…Effect of CDNF in a novel combination stressor model of Parkinson’s disease
Objective: In this study, our first aim was to develop a model for Parkinson's disease (PD) that would exhibit the alpha-synuclein (αSyn) aggregation pathology and…Effects of a novel neurotrophic compound in an animal model of Parkinson’s disease
Objective: Investigate the neuroprotective effect of a novel compound in an animal model of Parkinson’s disease. Background: Cerebral dopamine neurotrophic factor (CDNF) and mesencephalic astrocyte-derived…Clove mediated Rescue in Parkinson’s Disease involves modulation of p53 and Sestrin2 in SHSY5Y cell line model
Objective: The study analyzed the neuroprotective effect of ethanolic extract of clove against Parkinson’s disease (PD) type toxicity in SHSY5Y cell line model and interrogation…Phase 2 study evaluating safety, PK/PD, biomarkers, and efficacy of ANX005 in patients with Huntington’s disease (HD)
Objective: To assess the safety, PK/PD, exploratory biomarkers, and efficacy of ANX005 in patients with, or at risk for, manifest HD. Background: Increased complement activation…Pharmacological activation of Rev-erbα Provides Neuroprotection against Parkinson’s Disease
Objective: In this study, we investigated the effects of SR9009, a Rev-ERB agonist, on the dopaminergic system in the MPTP model of PD. Background: Circadian…STATINS IN PARKINSON’S DISEASE: INFLUENCE ON MOTOR PROGRESSION
Objective: To evaluate whether long-term statin use may affect motor progression in a large cohort of de novo patients with Parkinson's Disease. Background: Statins are…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 15
- Next Page »